{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"33"}],"title":"No Peripheral Sensory Neuropathy"},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"title":"Peripheral Sensory Neuropathy"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"description":"Measured by Common Terminology Criteria for Adverse Events (CTCAE) version 5. Incidences of CIPN (grade 2 or higher), pain, fatigue, nausea, and anxiety will be compared between treatment arms using Chi-squared or Fisher's exact tests as appropriate.","groups":[{"description":"Patients undergo acupuncture during chemotherapy infusion on day 1 and fluorouracil pump disconnect on day 3 of each biweekly chemotherapy infusion over 12 weeks. Patients also undergo self-administered acupressure over 11 minutes daily for 12 weeks and undergo standard of care oral cryotherapy.\n\nAcupuncture Therapy: Undergo acupuncture\n\nAcupressure Therapy: Undergo acupressure\n\nOral Cryotherapy: Undergo oral cryotherapy\n\nQuestionnaire Administration: Ancillary studies\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG000","title":"Arm I (Acupuncture, Acupressure, Cryotherapy)"},{"description":"Patients undergo standard of care oral cryotherapy.\n\nOral Cryotherapy: Undergo oral cryotherapy\n\nQuestionnaire Administration: Ancillary studies\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG001","title":"Arm II (Cryotherapy)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Frequency of Chemotherapy-Induced Peripheral Neuropathy (CIPN)","reportingStatus":"POSTED","timeFrame":"3 months","title":"Number of Participants With Grade 2 or Higher Chemotherapy-Induced Peripheral Neuropathy","type":"SECONDARY","unitOfMeasure":"Participants"}